

# Luis Agüera-Ortiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8334832/publications.pdf>

Version: 2024-02-01

26  
papers

1,584  
citations

623734

14  
h-index

610901

24  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2246  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 195-202.	0.8	493
2	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 929-938.	2.6	306
3	Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimer's and Dementia</i> , 2017, 13, 84-100.	0.8	167
4	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	2.2	166
5	Anticholinergic Drugs in Geriatric Psychopharmacology. <i>Frontiers in Neuroscience</i> , 2019, 13, 1309.	2.8	68
6	Psychosis and dementia: risk factor, prodrome, or cause?. <i>International Psychogeriatrics</i> , 2018, 30, 209-219.	1.0	49
7	Recommendations for the Nonpharmacological Treatment of Apathy in Brain Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 410-420.	1.2	41
8	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	2.6	39
9	Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management. <i>Frontiers in Psychiatry</i> , 2021, 12, 638651.	2.6	39
10	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	3.6	28
11	Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 119-147.	1.2	28
12	Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study. <i>International Psychogeriatrics</i> , 2017, 29, 2081-2093.	1.0	27
13	Structural correlates of apathy in Alzheimer's disease: a multimodal MRI study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 922-930.	2.7	27
14	Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association. <i>Frontiers in Psychiatry</i> , 2020, 11, 380.	2.6	22
15	A survey on the prevalence of apathy in elderly people referred to specialized memory centers. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1369-1377.	2.7	16
16	Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics. <i>Parkinson's Disease</i> , 2021, 2021, 1-11.	1.1	16
17	Prevalence and clinical correlates of restless legs syndrome among psychogeriatric patients. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1252-1259.	2.7	13
18	The "CHROME" criteria: Tool to optimize and audit prescription quality of psychotropic medications in institutionalized people with dementia. <i>International Psychogeriatrics</i> , 2020, 32, 315-324.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study. BMC Psychiatry, 2016, 16, 352.	2.6	9
20	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. Journal of Alzheimer's Disease, 2022, 88, 1203-1228.	2.6	7
21	The black hole of the transition process: dropout of care before transition age in adolescents. European Child and Adolescent Psychiatry, 2023, 32, 1285-1295.	4.7	4
22	Staging of depressive disorders: Relevance of resistance to treatment and residual symptoms. Journal of Psychiatric Research, 2020, 129, 234-240.	3.1	3
23	Syndrome-Based Prescription to Optimize Psychotropics: Are CHROME Criteria a Game Changer?. Frontiers in Psychiatry, 2021, 12, 662228.	2.6	3
24	In-Person and Remote Workshops for People With Neurocognitive Disorders: Recommendations From a Delphi Panel. Frontiers in Aging Neuroscience, 2021, 13, 747804.	3.4	3
25	Looking for navigation charts for the journey through dementia. International Psychogeriatrics, 2021, 33, 747-749.	1.0	0
26	¿Quo vadis Alois?. Medicina Clínica, 2020, 155, 491-493.	0.6	0